

Philippe Lucas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8113818/publications.pdf>

Version: 2024-02-01

24
papers

1,666
citations

516710

16
h-index

713466

21
g-index

24
all docs

24
docs citations

24
times ranked

1553
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use. <i>International Journal of Drug Policy</i> , 2013, 24, 511-516.	3.3	257
2	Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada. <i>Current Drug Abuse Reviews</i> , 2013, 6, 30-42.	3.4	242
3	Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. <i>International Journal of Drug Policy</i> , 2017, 42, 30-35.	3.3	202
4	Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. <i>Journal of Headache and Pain</i> , 2018, 19, 37.	6.0	126
5	Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. <i>Drug and Alcohol Review</i> , 2016, 35, 326-333.	2.1	124
6	Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. <i>Harm Reduction Journal</i> , 2019, 16, 9.	3.2	94
7	Cannabis as an Adjunct to or Substitute for Opiates in the Treatment of Chronic Pain. <i>Journal of Psychoactive Drugs</i> , 2012, 44, 125-133.	1.7	91
8	Cannabis as a substitute for alcohol and other drugs: A dispensary-based survey of substitution effect in Canadian medical cannabis patients. <i>Addiction Research and Theory</i> , 2013, 21, 435-442.	1.9	82
9	Barriers to access for Canadians who use cannabis for therapeutic purposes. <i>International Journal of Drug Policy</i> , 2014, 25, 691-699.	3.3	73
10	Rationale for cannabis-based interventions in the opioid overdose crisis. <i>Harm Reduction Journal</i> , 2017, 14, 58.	3.2	71
11	Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada. <i>Drug and Alcohol Review</i> , 2019, 38, 781-789.	2.1	60
12	Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use. <i>Journal of Psychopharmacology</i> , 2016, 30, 601-607.	4.0	46
13	Cannabis Significantly Reduces the Use of Prescription Opioids and Improves Quality of Life in Authorized Patients: Results of a Large Prospective Study. <i>Pain Medicine</i> , 2021, 22, 727-739.	1.9	45
14	Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. <i>Journal of Psychiatric Research</i> , 2019, 111, 134-139.	3.1	42
15	Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada. <i>International Journal of Drug Policy</i> , 2017, 47, 1-8.	3.3	36
16	Moral regulation and the presumption of guilt in Health Canada's medical cannabis policy and practice. <i>International Journal of Drug Policy</i> , 2009, 20, 296-303.	3.3	23
17	It can't hurt to ask; a patient-centered quality of service assessment of health canada's medical cannabis policy and program. <i>Harm Reduction Journal</i> , 2012, 9, 2.	3.2	15
18	Reprint of: Survey of medicinal cannabis use among childbearing women: Patterns of its use in pregnancy and retroactive self-assessment of its efficacy against "morning sickness". <i>Complementary Therapies in Clinical Practice</i> , 2009, 15, 242-246.	1.7	12

#	ARTICLE	IF	CITATIONS
19	Reductions in alcohol use following medical cannabis initiation: results from a large cross-sectional survey of medical cannabis patients in Canada. <i>International Journal of Drug Policy</i> , 2020, 86, 102963.	3.3	11
20	Self-reported reductions in tobacco and nicotine use following medical cannabis initiation: Results from a cross-sectional survey of authorized medical cannabis patients in Canada. <i>Journal of Substance Abuse Treatment</i> , 2021, 130, 108481.	2.8	6
21	Healthcare provider and medical cannabis patient communication regarding referral and medication substitution: the Canadian context. <i>Journal of Cannabis Research</i> , 2022, 4, .	3.2	5
22	The Medical Cannabis Standards Engagement Evaluation and Dissemination (SEED) project: A community-based research approach to self-regulating medical cannabis dispensaries in Canada. <i>International Journal of Drug Policy</i> , 2020, 78, 102708.	3.3	1
23	Perspectives on Healing and Recovery from Addiction with Ayahuasca-Based Therapy Among Members of an Indigenous Community in Canada. , 2021, , 171-188.		1
24	The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients. <i>Journal of Cannabis Research</i> , 2021, 3, 34.	3.2	1